The government is expected to pay lower prices for Ozempic and Wegovy starting in 2027. The Trump administration will decide whether to expand coverage for millions of Americans.

Now, Mr. Trump can build upon the provision in the Inflation Reduction Act that allows Medicare to negotiate prices on certain drugs. By pushing for tougher agreements with pharma

Announcing the 15 medicines chosen for the second round of negotiations is one of the Biden administration’s final health policy acts.

The US plans to slash the price it pays for the Novo Nordisk A/S blockbusters Ozempic and Wegovy, the latest drugs to be targeted under legislation that’s expected save the government more than $200 billion over a decade.

Biden administration says popular weight loss drugs have been added to Medicare’s list of medications that will be negotiated directly between the government and drug manufacturers

The U.S. government named 15 drugs that will be subject to the second round of price negotiations by Medicare, including Ozempic and Wegovy, the drugs at the center of the weight-loss craze. The Biden administration said the drugs account for $41 billion in annual Medicare spending,

Biden's administration announced weight loss drugs Ozempic and Wegovy will be included on Medicare's list of medications subject to direct price negotiations.

Ozempic and Wegovy are among the 15 drugs added to Medicare's list of medications that will be negotiated for lower prices. This is part of an effort to lower prescription drug prices for Medicare recipients.

Medicare enrollees, however, still won’t be able to access the drugs for obesity under a federal law that prohibits the program from paying for weight loss treatments. Right now

The popular weight-loss drugs were added to Medicare’s list of prices negotiated directly between the government and drug manufacturers.